COMPARATIVE PHARMACOKINETICS OF 3'-AZIDO-3'-DEOXYTHYMIDINE (AZT) AND 3'-AZIDO-2', 3'-DIDEOXYURIDINE (AZDDU) IN MICE
- 1 November 1989
- journal article
- research article
- Vol. 17 (6), 590-594
Abstract
The pharmacokinetics of 3''azido-3''deoxythymidine (AZT) and 3''-azido-2'',3''-dideoxyuridine (AZddU, CS-87), active anti-HIV compounds, were characterized in uninfected mice. Sensitive and specific HPLC techniques were used to quantitate AZT and AZddU concentrations in serum and brain homogenates following iv doses of 50 mg/kg and 250 mg/kg. The pharmacokinetic parameters of t1/2, Clt, and Vss were similar for both compounds at each dose; however, Clt and Vss decreases at the higher dose, indicating a dose dependency. At the 50 mg/kg doses, the Clt of AZddU and AZT was 1.27 liters/hr/kg and 1.38 liters/hr/kg, respectively, which is analogous to the clearance value of AZT observed in humans. Brain/serum concentration ratios for AZddU tended to be greater than those obtained for AZT and were significantly different at the 50 mg/kg dose, being 0.234 .+-. 0.282 for AZddU and 0.064 .+-. 0.025 for AZT.This publication has 10 references indexed in Scilit:
- Pharmacokinetics and saturable renal tubular secretion of zidovudine in ratsJournal of Pharmaceutical Sciences, 1989
- Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cellsJournal of Medicinal Chemistry, 1989
- Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complexJAMA, 1988
- PYRIMIDINE DIDEOXYRIBONUCLEOSIDES - SELECTIVITY OF PENETRATION INTO CEREBROSPINAL-FLUID1988
- Mean Residence Time Concepts for Pharmacokinetic Systems with Nonlinear Drug Elimination Described by the Michaelis–Menten EquationPharmaceutical Research, 1988
- THE DISPOSITION AND METABOLISM OF 2',3'-DIDEOXYCYTIDINE, AN INVITRO INHIBITOR OF HUMAN T-LYMPHOTROPHIC VIRUS TYPE-III INFECTIVITY, IN MICE AND MONKEYS1987
- Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseasesClinical Pharmacology & Therapeutics, 1987
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985
- Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDSScience, 1984